24小时热门版块排行榜

>论坛更新日志 (3195)
>虫友互识 (512)
>休闲灌水 (179)
>导师招生 (112)
>文献求助 (102)
>硕博家园 (56)
>论文投稿 (45)
>博后之家 (37)
>论文道贺祈福 (36)
>基金申请 (35)
>考博 (33)
>考研 (30)
>教师之家 (28)
>找工作 (22)
>招聘信息布告栏 (17)
>公派出国 (14)

返回列表

1949stone

荣誉版主 (知名作家)

海纳百川

应助: 95 (初中生)
贵宾: 2.38
金币: 2622.9
散金: 3394
红花: 177
沙发: 8
帖子: 9829
在线: 2692.8小时
虫号: 765987
注册: 2009-05-08
性别: GG
专业: 药物分析
管辖: 分子生物

[交流] Guidance for Industry-Electronic Source Data in Clinical Investigations 已有2人参与

I. INTRODUCTION
This guidance provides recommendations to sponsors, Contract Research Organizations (CROs), clinical investigators, and others involved in the capture, review, and retention of electronic source data in FDA-regulated clinical investigations.2 In an effort to streamline and modernize clinical investigations this guidance promotes capturing source data in electronic form, and it is intended to assist in ensuring the reliability, quality, integrity, and traceability of data from electronic source to electronic regulatory submission.
This guidance addresses source data in clinical investigations used to fill the predefined fields in an electronic case report form (eCRF), according to the protocol. The guidance discusses the following topics related to electronic source data:
 Identification and specification of authorized source data originators
 Creation of data element identifiers to facilitate examination of the audit trail by
sponsors, FDA, and other authorized parties
 Ways to capture source data into the eCRF using either manual or electronic methods
 Clinical investigator(s) responsibilities with respect to reviewing and retaining electronic
data
 Use and description of computerized systems in clinical investigations
This guidance is intended to be used together with the FDA guidance for industry on Computerized Systems Used in Clinical Investigations (the computerized systems guidance),and FDA regulation on Electronic Records and Electronic Signatures.4 Electronic structures and standards related to electronic submissions are out of scope for this guidance.
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.[ Last edited by 1949stone on 2014-1-23 at 08:26 ]

回复此楼